U.S. markets close in 5 hours 17 minutes

Aridis Pharmaceuticals, Inc. (ARDS)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
6.18-0.27 (-4.20%)
As of 9:52AM EDT. Market open.
Sign in to post a message.
  • D
    Danel
    Im in and looking to go past 10
    Bullish
  • B
    Bulls
    $CTXR conversation
    Just tweeted by Citius
    Citius Pharma
    @CitiusPharma
    ·
    1h
    NoveCite i-MSCs development is progressing with ongoing data from our sheep acute respiratory distress syndrome #ARDS model demonstrating impressive interim results. Studies are expected to be completed in the second quarter. https://ir.citiuspharma.com/press-releases/detail/135/citius-pharmaceuticals-issues-shareholder-letter-with $CTXR #COVID19 #Health #Pharm
    Bullish
  • S
    Shlomo
    Low valuation of 60 million /Shares Out 10 million / Phase 3 readout within 3 months targeting $6 BILLION Market = undiscovered stock with MASSIVE upside a potential 10 bagger and more .GL

    "Continued enrolling global Phase 3 clinical trial of AR-301 in patients with ventilator associated pneumonia (VAP) including patients who presented with VAP secondary to ventilator placement for COVID-19. Interim futility analysis is expected in 1H 2021; full data is expected in YE 2021."

    Aridis has several therapies in the pipeline. The most advanced candidate is AR-301, which is currently in a phase 3 study for the treatment of hospital-acquired pneumonia (HAP) and ventilator-associate pneumonia (VAP), which is derived from the gram-positive bacterium Staphylococcus aureus (S. aureus ) was acquired. Bernardino believes that the drug will have regulatory approval by 2022 and that the AR-301 projects could generate annual sales of approximately $ 700 million by 2030.
    Bullish
  • W
    Webel with cause
    $TBP.TO conversation
    Tweet from Dr. Guy Chamberland this morning
    @DrGChamberland
    I promised a history lesson on #ARDS-003, here it is. ARDS-003 is a sterile nano-emulsion of a synthetic compound that meets pharma quality standard. It’s administered in form of a sterile injection for the Tx of systemic inflammation, in conditions like #sepsis & #ARDS.
    #ARDS-003 has been studied for over 12 yrs by scientists associated with @DalhousieU. It has peer-reviewed data & strong IP. It works by activating a receptor encoded by the CNR2 gene & is expected to dampen an extreme inflammatory response.
    When the #COVID19 pandemic hit, $TBP #adapted & #pivoted. On April 27, 2020, we announced ARDS-003 as drug candidate as potential #therapy for preventing #ARDS in patients with COVID-19 & later added a 2nd indication, #sepsis.
    Jun & July 2020, initiated tox. studies: microsome & hepatocyte stability, protein binding assays, IV compatibility, hERG assay - cardiovascular safety, single dose IV pharmacokinetic studies in rats & dogs, & reverse mutation & #invitro micronucleus assays for genotoxicity
    In July 2020, we completed a pre-IND meeting with @FDA and a pre-CTA meeting with @GovCanHealth to seek recommendations and advice on our preclinical and clinical development programs in patients with #COVID19.
    Also in July 2020, our clinical team began setting up a Phase 1 #clinicaltrial in #Canada, in healthy volunteers. Further, in August 2020, we engaged Dalton Pharma Services for cGMP #Manufacturing of ARDS-003 nano-emulsion.
    In Oct a research alliance formed w/ Targeted Pharma & GMU to assess our drug with & without antiviral drugs to prevent & treat #SARS-COV-2 in animals. This is major. Why? As we know, only in vitro SARS-CoV2 infection models exist & there is no established ARDS in vivo model
    In Dec @tetrabiopharma announced exciting news! Completed #IND-enabling #toxicology, clearing way for human clinical trials for its novel drug candidate #ARDS-003. #DYK as few as 1 out of 1K compounds cross this threshold & make it into Phase 1 trials? We did it! @jazzpharma

    #RESULTS? Here’s what I can share: our #drug is highly selective activator of CB2R on immune cells involved in the inflammatory response to pathogens. It decreases inflammation & immune cell activation in exp. #sepsis including endotoxemia & peritonitis-induced sepsis models
    Further, it reduces levels of key proinflammatory mediators including, cytokines (TNF, IL-6, MCP-1, IL1beta), chemokines and adhesion molecules, responsible for hyperinflammation in #sepsis models.
    It also activates the #CB2 receptor and reduces #inflammation and #fibrosis in #lunginjury models, reduces organ #inflammation in experimental models of #ocular (pan-uveitis) & #bladder (interstitial cystitis) inflammation.
    #ARDS-003 shows #efficacy in reducing cellular changes driving fibrosis using lung fibroblasts from IPF patients & compared to clinical drugs, #dexamethasone, #prednisolone & #nepafenac, activation of #CB2 receptor provides effective early reduction in ocular inflammation
    A recent market report on #ARDS est. the global addressable market to rise to $3Bn USD by 2030 & annual sales of drugs used to treat #sepsis are expected to rise to $5.9B by 2026. We believe our drug will play a major role in addressing the needs of these markets.
    The impacts after illness represents a major component of our drug dev. program. Our #focus is not only on patient #survival, but also on post survival outcomes such as secondary infection, multi organ injury, and the development of #fibrosis. #savinglives #harmreduction
    There you have it folks! A summary of #ARDS-003, a potential drug candidate for #COVID19, #ARDS & #sepsis. Stay tuned for more updates!
  • t
    tim
    $ATHX conversation
    Athersys released a new video today to provide information about #ARDS, the critical need for new treatments and perspective on the encouraging results from the MUST-ARDS exploratory study from physician investigators and others. $ATHX
    Bullish
  • t
    tim
    $ATHX conversation
    Geoff Bellingan Retweeted
    @87_boogie. 4h
    #ARDS is the leading cause of death in severe #COVID19 patients listen to @GBellingan discuss the data seen in a pneumonia induced ARDS trial completed by @athersys in 2019 which led to fast track designation from @US_FDA

    https://www.youtube.com/watch?v=9wt6JOvEXVM
    Dr. Geoff Bellingan: MultiStem Cell Therapy in ARDS
    www.youtube.com
    Bullish
  • W
    Whino
    $RLFTF conversation
    RT wrote a very POSITIVE blurb on their LinkedIn profile today about the analyst report. They wrote the below POSITIVE information KNOWING the RESULTS. If one KNEW the results were negative, the BELOW enthusiastic tone would not be written in a blurb TODAY. Why would they write the below if they knew the results were not positive? Hopefully this is a thinly veiled hint.

    RT LinkedIn Blurb: "What a Relief! Read the comprehensive analyst report published by Bob Pooler, ValualtionLab “Prepared to be transformational”. Bob is convinced that 2021 will be a transformational year for RELIEF THERAPEUTICS Holding AG built upon #RLF100 IV potentially reaching positive results in its pivotal U.S. phase 2b/3 trial in #COVID19 induced #ARDS, triggering a potential U.S. Emergency Use Authorization #EUAA) and first commercial sales, including potential stockpiling orders."
  • M
    MAK
    $CTSO conversation
    Christian Steiner
    Senior VP Sales & Marketing bei CytoSorbents Corp.
    1d • 1 day ago

    More and more hospitals are adding CytoSorb therapy to their armamentarium to fight cytokinestorm and hyperinflammation in COVID19, septic shock and other diseases or syndromes. CytoSorb has been part of COVID19 therapy in more than 20 countries now in connection with ECMO, with CRRT (acute continuous dialysis) or as a stand-alone hemoperfusion...
    #cytokinestorm #cytosorb #covid19 #sepsis #ards #ecmo #immunotherapy #perfusionist
  • B
    BOSCO
    "I am honored that a stem cell luminary as powerful as Dr. Amit Patel, the first physician to inject stem cells into the human heart, has entrusted our Company with his potent and promising technology as applied to brain injuries," said Timothy Dixon, President and CEO of TSOI. "We look forward to filing an IND for this technology before year end."

    Dr. Amit Patel posted on his Twitter today ...Congratulations to our multi-institutional team who received FDA IND clearance for off the shelf umbilical cord MSCs to treat #covid19 #ARDS in a repeat dosing strategy #msc #jadicell
  • r
    rahdbob2
    $ATHX conversation
    #MultiStem cell therapy is being evaluated in #clinicaltrials for both #stroke and #COVID19 induced #ARDS. New evidence suggests there may be correlation due to increased blood clotting
    Bullish
  • D
    DavidO
    Just posted on FB by NeuroRx:

    Few effective drug options exist for COVID-19 induced Acute Respiratory Distress Syndrome (#ARDS). We're committed to addressing this unmet need as quickly as possible. Learn about our Expanded Access Program & our journey to develop #Aviptadil (#RLF100) for Critical COVID-19 with respiratory failure. https://www.neurorxpharma.com/our-services/rlf-100/

    #ARDS #SARSCOV2 #RLF100 #COVD19 #coronavirus
  • t
    tim
    $ATHX conversation
    Back in April of 2019 Ms. Eileen Rubin, President of the ARDS Foundation and ARDS survivor, shared her perspective on ARDS and the severe impact it has on patients at an Athersys Investor day, see her in link below...
    @athersys 11m
    Some patients that survive #ARDS have trouble getting back to functional independence & the quality of life they once had. If you need support, visit the ARDS Foundation, dedicated to increasing ARDS awareness & supporting patients & families. https://ardsglobal.org
    @ardsglobal
    Acute Respiratory Distress Syndrome affects 200,00 people in the US each year. About half will die from it, many others will have life-long complications.
    Acute Respiratory Distress Syndrome affects 200,00 people in the US each year. About half will die from it, many others will have life-long complications.
    ardsglobal.org
    Bullish
  • G
    GRID
    $RLFTF conversation
    Not new news I know, but just posted on LinkedIn by Relief (I guess this board is quite a bit faster than their marketing department):

    "What a Relief! Read the comprehensive analyst report published by Bob Pooler, ValualtionLab “Prepared to be transformational”. Bob is convinced that 2021 will be a transformational year for RELIEF THERAPEUTICS Holding AG built upon #RLF100 IV potentially reaching positive results in its pivotal U.S. phase 2b/3 trial in #COVID19 induced #ARDS, triggering a potential U.S. Emergency Use Authorization #EUAA) and first commercial sales, including potential stockpiling orders. "
  • t
    tim
    $ATHX conversation
    Japan's MHLW right on schedule...

    Our partner in Japan, @HealiosJapan, has officially received Orphan Designation from the PMDA for their #ARDS program, which is meant to offer priority consultation and expedited review for the potential approval of #MultiStem Cell Therapy.
    Bullish
  • t
    tim
    $ATHX conversation
    1/29/20
    $ATHX is encouraged by the results from our exploratory #ARDS study & the potential to help patients. The data showed that surviving patients who received MultiStem® experienced meaningfully better quality of life compared to those who received placebo. https://tinyurl.com/sa5gt6g
  • C
    CavScout1969
    $MESO $ATHX $PSTI

    #MultiStem cell therapy is being evaluated in #clinicaltrials for both #stroke and #COVID19 induced #ARDS. New evidence suggests there may be correlation due to increased blood clotting. #StrokeMonth

    New Tweet. Interesting indeed. BARDA should take a look at this too as part of the collaboration
  • W
    WolfZen
    $RLFTF conversation
    I’ve a wake up smell the coffee message here whether you like it or not. NeuroRx Tweet last night was a slightly concerning confirmation that there are other effective drug options out there which we knew, but moreover, this other options are in the queue for approval too, whether that is imminent or not, fact is the FDA knows the value to the company who is approved for the first therapy, on this basis I think a delaying exercise will take place if it hasn’t already, to let BP shuffle up the queue, if you think that’s rubbish then you need to take a long reality check -

    ‘Few effective drug options exist for COVID-19 induced Acute Respiratory Distress Syndrome (#ARDS). We're committed to addressing this unmet need as quickly as possible. Learn about our Expanded Access Program & our journey to develop #Aviptadil (#RLF100) for Critical COVID-19 with respiratory failure. https://www.neurorxpharma.com/our-services/rlf-100/

    #ARDS #SARSCOV2 #RLF100 #COVD19 #coronavirus‘
    We Treat COVID-19 Respiratory Failure - NeuroRx
    www.neurorxpharma.com
    Neutral
  • t
    tim
    $ATHX conversation
    $ATHX is pleased to share that our partner @HealiosJapan announced plans to initiate a clinical trial for the treatment of #ARDS using #MultiStem https://ssl4.eir-parts.net/doc/4593/tdnet/1645151/00.pdf
  • P
    Paul
    With a product in phase 3 and two in phase 2 I am VERY excited about this company! Three more in pre-clinical. I would expect a nice pop every time one moves up a phase.